Precision BioSciences prices $125M underwritten offering
The clinical-stage biotech priced an underwritten offering to back its ARCUS-based gene editing therapies.
Image: Precision BioSciences, Inc.
Precision BioSciences priced a $125 million underwritten public offering on Nov. 5, according to a press release [1]. The transaction comprises common stock alongside pre-funded warrants [1].
The clinical-stage biotechnology company develops in vivo gene editing treatments using its proprietary ARCUS platform [1]. The system operates as a specialized editing mechanism designed to insert, excise, or repair specific DNA sequences in therapeutic targets [1].
The offering supplies capital as the company progresses clinical-stage assets built on the ARCUS genome editing platform [1].
Questions and answers
How much capital did Precision BioSciences price?
Precision BioSciences priced an underwritten offering of $125 million [1].
What technology does Precision BioSciences use?
The company uses ARCUS, a proprietary gene editing platform, to develop in vivo therapies [1].
